دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Non-viral infections and antimicrobial resistance in the time of COVID-19: what to expect?
Lyudmila Boyanova, Rumyana Markovska, Ivan Mitov & Raina Gergova
doi : 10.1080/17512433.2022.2108403
Expert Review of Clinical Pharmacology, Volume 15, Issue 8 (2022)
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy
Jihei Sara Lee & Chan Yun Kim
doi : 10.1080/17512433.2022.2112948
Ocular redness, or conjunctival hyperemia, is a common ophthalmic sign associated with reduced quality of life. For redness without apparent underlying pathology, topical ophthalmic decongestants have been widely used.
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion
Louise Carton, Romain Icick, Sébastien Weibel, Maurice Dematteis, Etienne Kammerer, Anne Batisse & Benjamin Rolland
doi : 10.1080/17512433.2022.2112950
Lisdexamfetamine dimesylate (LDX) is a prodrug approved for attention deficit/hyperactivity disorder and for moderate-to-severe binge eating disorder in adults in some countries.
Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder
William V. Bobo, Bailey Van Ommeren & Arjun P. Athreya
doi : 10.1080/17512433.2022.2112949
The efficacy of antidepressants for patients with major depressive disorder (MDD) varies from individual to individual, making the prediction of therapeutic outcomes difficult. Better methods for predicting antidepressant outcomes are needed.
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics
Thanaporn Wattanakul, Palang Chotsiri, Ivan Scandale, Richard M. Hoglund & Joel Tarning
doi : 10.1080/17512433.2022.2113388
Developing and evaluating novel compounds for treatment or prophylaxis of emerging infectious diseases is costly and time-consuming. Repurposing of already available marketed compounds is an appealing option as they already have an established safety profile.
The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock
Timothy E. Albertson, James A. Chenoweth, Justin C. Lewis, Janelle V. Pugashetti, Christian E. Sandrock & Brian M. Morrissey
doi : 10.1080/17512433.2022.2110067
Septic and vasoplegic shock are common types of vasodilatory shock (VS) with high mortality. After fluid resuscitation and the use of catecholamine-mediated vasopressors (CMV), vasopressin, angiotensin II, methylene blue (MB), and hydroxocobalamin can be added to maintain blood pressure.
Colony stimulating factors for prophylaxis of chemotherapy-induced neutropenia in children
Heeyeon Kim & Shaker A Mousa
doi : 10.1080/17512433.2022.2110066
Febrile neutropenia (FN) is one of the complications of chemotherapy that can increase the risk of infection and mortality. Granulocyte colony-stimulating factors (G-CSFs) are used in practice to prevent and treat episodes of neutropenia. The use of G-CSFs in children with cancer has not been studied much for primary prophylaxis of FN.
Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials
Dan Jiang, Zaiwei Song, Yang Hu, Fei Dong & Rongsheng Zhao
doi : 10.1080/17512433.2022.2106968
The bleeding risk associated with Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy remains to be understood. This systematic review aims to evaluate BTKi monotherapy related bleeding risk.
Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials
Chao-Kun Chen, Teng-Song Weng, Yu-Hung Chen, Jui- Heng Kao & Chien- Ming Chao
doi : 10.1080/17512433.2022.2103539
This study investigated the clinical efficacy sofosbuvir/daclatasvir (SOF-DCV) in patients with COVID-19.
Risk of osteoporosis in patients with atrial fibrillation with and without oral anticoagulant therapy
Woldesellassie M. Bezabhe, Jan Radford, Barbara C. Wimmer, Mohammed S. Salahudeen, Ivan Bindoff, Tristan Ling & Gregory M. Peterson
doi : 10.1080/17512433.2022.2103540
We aimed to compare the risk of developing osteoporosis in patients prescribed warfarin or direct-acting oral anticoagulants (DOACs) with those with no therapy.
